









市場行情
/
股票
/
nasdaq-cmps
/

Compass Pathways PLC

CMPS

6.680USD

-0.165-2.41%

收盤 12/26, 16:00（美東）報價延遲15分鐘

641.29M總市值

虧損本益比TTM



Compass Pathways PLC

6.680

-0.165-2.41%

概覽公司財務分析

概覽

公司

財務

分析

關於 Compass Pathways PLC 公司

Compass Pathways plc is a United Kingdom-based biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health. The Company is engaged in treating mental health conditions focused on rapid and durable responses through the development of its investigational COMP360 psilocybin treatment. COMP360 is its psilocybin formulation that includes its pharmaceutical-grade polymorphic crystalline psilocybin, optimized for stability and purity. The Company’s initial focus is on treatment-resistant depression (TRD), comprising patients who are inadequately served by the current treatment paradigm. It commenced its Phase III program evaluating its COMP360 psilocybin treatment in TRD. In addition, the Company has ongoing Phase II trials in PTSD and anorexia nervosa. It also provides support to research institutions conducting investigator-initiated studies with COMP360 psilocybin in areas of serious unmet need.

Compass Pathways PLC簡介



公司代碼CMPS

公司名稱Compass Pathways PLC

上市日期Sep 18, 2020

CEONath (Kabir)

員工數量166

證券類型Depository Receipt

年結日Sep 18

公司地址3Rd Floor, 1 Ashley Road

城市ALTRINCHAM

上市交易所NASDAQ OMX - NASDAQ BASIC

國家United Kingdom

郵編WA14 2DT

電話17166766461

網址https://compasspathways.com/

公司代碼CMPS

上市日期Sep 18, 2020

CEONath (Kabir)

Compass Pathways PLC公司高管



名稱

名稱/職務

職務

持股

持股變動

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

Dr. Guy Goodwin

Chief Medical Officer

1.99K

Mr. Justin Gover

Director

Ms. Daphne Karydas

Independent Director

Dr. Wayne Joseph Riley, M.D.

Independent Director

名稱

名稱/職務

職務

持股

持股變動

Dr. Robert McQuade, Ph.D.

Independent Director

1.59M

Mr. Thomas Lonngren

Independent Director

89.05K

Mr. Kabir Nath

Chief Executive Officer, Executive Director

29.07K

+944.11%

Mr. David Norton

Independent Director

20.36K

+17.06%

Dr. Annalisa M. Jenkins

Independent Director

19.48K

+17.97%

Ms. Teri Loxam

Chief Financial Officer

11.21K

-86.53%

收入明細

由於公司未披露，未能獲取相關數據

由於公司未披露，未能獲取相關數據

業務

地區

由於公司未披露，未能獲取相關數據

股東統計

更新時間: 12月15日週一

持股股東

股東類型

持股股東

佔比

RTW Investments L.P.

9.07%

Deep Track Capital LP

8.19%

Atai Life Sciences AG

6.03%

GMT Capital Corp.

2.96%

Millennium Management LLC

2.83%

其他

70.93%

持股股東

佔比

RTW Investments L.P.

9.07%

Deep Track Capital LP

8.19%

Atai Life Sciences AG

6.03%

GMT Capital Corp.

2.96%

Millennium Management LLC

2.83%

其他

70.93%

股東類型

持股股東

佔比

Hedge Fund

27.73%

Investment Advisor/Hedge Fund

15.31%

Investment Advisor

11.88%

Individual Investor

6.10%

Corporation

6.03%

Research Firm

4.24%

Bank and Trust

1.63%

Venture Capital

0.68%

Endowment Fund

0.22%

其他

26.18%

機構持股



更新時間: 12月8日週一

報告期間

機構數

持股數

持股佔比

持股變動

2025Q4

283

57.38M

72.50%

+6.72K

2025Q3

301

57.46M

74.76%

+3.34M

2025Q2

285

53.63M

67.49%

+1.03M

2025Q1

275

52.65M

51.90%

+4.46M

2024Q4

270

31.64M

55.25%

-1.83M

2024Q3

260

33.66M

49.30%

+4.32M

2024Q2

262

29.34M

47.25%

+403.49K

2024Q1

263

28.00M

40.12%

+578.36K

2023Q4

271

23.51M

40.32%

+723.33K

2023Q3

272

22.78M

29.97%

+8.57M

股東持股明細



名稱

持股數

佔比

持股變動

變動比例

公告日期

RTW Investments L.P.

8.22M

8.57%

+2.68M

+48.46%

Jun 30, 2025

Deep Track Capital LP

8.83M

9.2%

-28.64K

-0.32%

Jun 30, 2025

Atai Life Sciences AG

6.91M

7.2%

Mar 05, 2025

GMT Capital Corp.

1.78M

1.86%

Jun 30, 2025

Millennium Management LLC

1.74M

1.82%

-1.03M

-37.20%

Jun 30, 2025

Tang Capital Management, LLC

1.30M

1.35%

-100.00K

-7.14%

Jun 30, 2025

ARK Investment Management LLC

1.65M

1.72%

-155.58K

-8.62%

Jun 30, 2025

Goldsmith (George Jay)

2.05M

2.14%

-129.33K

-5.93%

Mar 31, 2025

Malievskaia (Ekaterina)

2.03M

2.11%

-149.38K

-6.86%

Mar 31, 2025

UBS Financial Services, Inc.

1.40M

1.46%

+402.30K

+40.20%

Jun 30, 2025

持股ETF



更新時間: 12月6日週六

機構名稱

佔比

AdvisorShares Psychedelics ETF

8.41%

Simplify Propel Opportunities ETF

2.71%

ARK Genomic Revolution ETF

1.23%

Virtus LifeSci Biotech Clinical Trials ETF

0.95%

ALPS Medical Breakthroughs ETF

0.24%

ProShares Ultra Nasdaq Biotechnology

0.06%

Invesco Nasdaq Biotechnology ETF

0.06%

SPDR S&P International Small Cap ETF

0.06%

iShares Biotechnology ETF

0.04%

Putnam Sustainable Future ETF

AdvisorShares Psychedelics ETF

佔比8.41%

Simplify Propel Opportunities ETF

佔比2.71%

ARK Genomic Revolution ETF

佔比1.23%

Virtus LifeSci Biotech Clinical Trials ETF

佔比0.95%

ALPS Medical Breakthroughs ETF

佔比0.24%

ProShares Ultra Nasdaq Biotechnology

佔比0.06%

Invesco Nasdaq Biotechnology ETF

佔比0.06%

SPDR S&P International Small Cap ETF

佔比0.06%

iShares Biotechnology ETF

佔比0.04%

Putnam Sustainable Future ETF

佔比0%

分紅派息



近5年累計派現 0.00 美元

公告日期

分紅計劃

股權登記日

現金發放日

除權除息日

暫無數據

拆合股



公告日期

類型

比率

暫無數據

公告日期

類型

比率

暫無數據

常見問題

Compass Pathways PLC的前五大股東是誰？



Compass Pathways PLC的前五大股東如下：
RTW Investments L.P.
持有股份：8.22M
佔總股份比例：8.57%。
Deep Track Capital LP
持有股份：8.83M
佔總股份比例：9.20%。
Atai Life Sciences AG
持有股份：6.91M
佔總股份比例：7.20%。
GMT Capital Corp.
持有股份：1.78M
佔總股份比例：1.86%。
Millennium Management LLC
持有股份：1.74M
佔總股份比例：1.82%。